Donepezil benefits patients with moderate to severe Alzheimer’s diseaseBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e1718 (Published 08 March 2012) Cite this as: BMJ 2012;344:e1718
- Geoff Watts
A study of 295 patients with Alzheimer’s disease has shown that the drug donepezil and memantine, already used in the mild to moderate stage of the illness, are also beneficial in its moderate to severe stage.
“Overall this is an important study,” said Clive Ballard, one of the study’s coauthors and director of research at the Alzheimer’s Society. “It’s informed an issue where previously there wasn’t any evidence, and it’s allowed us to think about the drug treatment of Alzheimer’s disease in a smarter way.”
The new findings, reported in the New England Journal of Medicine (2012;136:893-903), are the outcome of the DOMINO trial funded by the Medical Research Council and the Alzheimer’s Society. This …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial